Advances in nanomedicines for malaria treatment

Aditya, N.P.; Vathsala, P G; Vieira, Verónica M.; Murthy, R. S. R.; Souto, Eliana B.

doi:10.1016/j.cis.2013.10.014

Cited by 95 publications

(61 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nanocarrier-based systems are providing new and powerful opportunities for targeting malaria-infected erythrocytes for the treatment of the disease [8,9]. The overall goal for effective antimalarial therapy is the achievement of high intra-cellular drug concentrations in pRBCs.…”

Section: Introductionmentioning

confidence: 99%

Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes

Sidhaye¹,

Bhuran²,

Zambare³

et al. 2016

Nanomedicine

View full text Add to dashboard Cite

Aim: The intra-erythrocytic development of the malarial parasite is dependent on active uptake of nutrients, including human serum albumin (HSA), into parasitized red blood cells (pRBCs). We have designed HSA-based nanoparticles as a potential drug-delivery option for antimalarials. Methods: Artemether-loaded nanoparticles (AAN) were designed and antimalarial activity evaluated in-vitro/in-vivo using Plasmodium falciparum/Plasmodium berghei species, respectively. Results: Selective internalisation of AAN into Plasmodiuminfected RBCs in preference to healthy erythrocytes was observed using confocal-imaging.In-vitro studies showed 50% dose reduction for AAN as compared to drug-only controls to achieve IC50 levels of inhibition. The nanoparticles exhibited 2-fold higher peak drug concentrations in RBCs with antimalarial activity at 50% of therapeutic doses in P.bergeiinfected mice. Conclusion: HSA-based nanoparticles offer safe and effective approach for selective targeting of antimalarial drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes

Sidhaye¹,

Bhuran²,

Zambare³

et al. 2016

Nanomedicine

View full text Add to dashboard Cite

show abstract

“…These situations warrant the application of novel drug delivery approaches, which have shown success in the past in overcoming the pharmacokinetic mismatches such as controlled release, bioavailability, stability, etc. to other drug molecules, which are in use to treat similar parasitic infections in general and malaria in particular (Date et al, 2007;Santos-Magalhães & Mosqueira, 2010;Aditya et al, 2013b). Thus, the aim of this research is to fabricate injectable (intraperitoneal; i.p.)…”

Section: Introductionmentioning

confidence: 99%

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

2014

View full text Add to dashboard Cite

Context: Artemether and lumefantrine combination therapy is well-accepted for uncomplicated malaria treatment. However, the current available formulation has several pharmacokinetic mismatches such as drug degradation in gastrointestinal tract, erratic absorption, etc. Hence, need of the hour is the injectable formulation, which can overcome the pharmacokinetic mismatch associated with current available formulation in the market. Objective: To fabricate artemether and lumefantrine co-loaded injectable nanostructured lipid carriers (NLCs) formulation. Materials and methods: Artemether and lumefantrine co-loaded NLCs were fabricated using homogenization followed by ultra-sonication method. Fabricated NLCs were evalauated for their physicochemical characteristics, and suitability of the formulation for malaria treatment was evaluated using in vivo animal model (Plasmodium berghei-infected mice). Results, discussion and conclusion: Artemether and lumefantrine co-loaded NLCs had a hydrodynamic diameter of $145 nm with the surface charge of À66 mV. Due to the lipophilic nature of both antimalarial drugs, both single drugs-loaded and co-loaded NLCs have shown high encapsulation efficiency, which is 84% for artemether and 79% for lumefantrine. In vitro drug release study has shown a biphasic drug release pattern, which has shown 63% artemether release and 45% of lumefantrine release over a time period of 30 h. Plasmodium berghei-infected mice treated with artemether and lumefantrine co-loaded NLCs showed better antimalarial activity with respect to parasitemia progression and survivability period.

show abstract

“…Dendritic cells have been an effective target for the delivery of vaccines as they form a part of both innate and acquired immunity and play a central role in triggering immune response after coming in contact with an antigen [118,119]. Polymeric nanoparticles such as PLGA, liposomes and virus-like nanoparticles have been studied for delivery of vaccines [120][121][122]. For example, PLGA nanoparticles have been used for mucosal immunization against hepatitis B [120].…”

Section: Nanoparticles For Vaccine Deliverymentioning

confidence: 99%

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Ponnappan

Chugh

2015

Pharm Med

View full text Add to dashboard Cite

Nanotechnology-based pharmaceutics is a fast emerging field in the diagnosis and therapy of a number of human diseases, including cancer. Nanoparticles offer a stable means to achieve targeted drug delivery to various cells and tissues. They have been investigated for drug delivery to different tumor tissues, to brain where the blood-brain barrier poses a significant problem in the delivery of effective therapeutic molecules, to ocular tissues and also for eliciting immune response via delivery of vaccines. Particularly, the small size of nanoparticles facilitates their easy access to a wide range of cells and tissues. Further, the size of nanoparticles can be controlled and their surface can be modified with desired ligands and receptors to specifically target cells of interest as well as achieve controlled drug release. Research is being carried out on numerous biological and synthetic nanoparticles. Diverse strategies are being developed to improve their stability, specificity and drug delivery efficiency. Nanoparticles have been also used in conjunction with cellpenetrating peptides for efficient drug delivery. Cellpenetrating peptides serve as efficient nanocarriers owing to their inherent ability to cross the plasma membrane barrier and deliver cargo to intracellular targets. Modification of nanoparticles with cell-penetrating peptides further increases their efficacy for increased permeation into varied cells and tissues. The current review focuses on different classes of nanoparticles and their application in the treatment of several types of diseases. Key PointsNanoparticle-based therapeutic drugs are widely used for the treatment of a number of diseases, including cancer.Ease of modulation of size and tuning of the nanoparticles with various ligands make them effective for formulation into specific drugs with increased therapeutic index and reduced toxicity.Successful pre-clinical and early phase clinical trials have promised the emergence of nanocarrier-based drugs.

show abstract

Advances in nanomedicines for malaria treatment

Cited by 95 publications

References 189 publications

Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes

Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

Nanoparticle-Mediated Delivery of Therapeutic Drugs

Contact Info

Product

Resources

About